GW Henssler & Associates Ltd. Purchases 16 Shares of Eli Lilly and Company (NYSE:LLY)

GW Henssler & Associates Ltd. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,047 shares of the company’s stock after buying an additional 16 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in Eli Lilly and Company were worth $928,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. State of Michigan Retirement System grew its holdings in Eli Lilly and Company by 12.6% in the first quarter. State of Michigan Retirement System now owns 269,704 shares of the company’s stock worth $209,819,000 after purchasing an additional 30,200 shares during the period. Financial Security Advisor Inc. boosted its position in shares of Eli Lilly and Company by 1.4% in the 1st quarter. Financial Security Advisor Inc. now owns 4,194 shares of the company’s stock worth $3,263,000 after purchasing an additional 58 shares in the last quarter. Naviter Wealth LLC grew its stake in shares of Eli Lilly and Company by 18.3% in the 1st quarter. Naviter Wealth LLC now owns 4,318 shares of the company’s stock worth $3,359,000 after buying an additional 668 shares during the last quarter. Saxon Interests Inc. bought a new position in Eli Lilly and Company during the 1st quarter valued at approximately $261,000. Finally, Azzad Asset Management Inc. ADV raised its stake in Eli Lilly and Company by 2.5% during the first quarter. Azzad Asset Management Inc. ADV now owns 1,814 shares of the company’s stock valued at $1,411,000 after buying an additional 45 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.9 %

Eli Lilly and Company stock opened at $904.05 on Wednesday. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The company has a market cap of $859.21 billion, a P/E ratio of 133.14, a P/E/G ratio of 3.24 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The business has a 50-day simple moving average of $918.30 and a two-hundred day simple moving average of $865.23.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Analysts predict that Eli Lilly and Company will post 14.05 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on LLY shares. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target on the stock. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Finally, Guggenheim upped their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,013.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.